Endothelial Dysfunction in Heart Failure: Mechanisms and Therapeutic Approaches

Author(s): Johann Bauersachs, Andreas Schafer

Journal Name: Current Vascular Pharmacology

Volume 2 , Issue 2 , 2004

Become EABM
Become Reviewer
Call for Editor


Endothelial dysfunction contributes to the development of impaired coronary and systemic perfusion as well as reduced exercise capacity in patients with congestive heart failure (CHF). Thereby endothelial dysfunction is assumed to have a fundamental impact on morbidity and potential mortality in this disease. Reduced bioavailability of nitric oxide (NO) and abundant formation of reactive oxygen species (ROS) within the vascular wall are the key determinants in endothelial dysfunction. The resulting imbalance between NO and ROS mainly results from neurohumoral activation associated with CHF. The excessive activation of the renin-angiotensinaldosterone and endothelin systems plays a pivotal role. Treatment with ACE inhibitors, angiotensin-, aldosterone-, and endothelin-antagonists has been shown to beneficially modulate endothelial dysfunction in CHF. Furthermore, antioxidants, L-arginine, cofactors of endothelial NO-synthase, and exercise training positively modulate endothelial function. This article reviews the current knowledge of the pathophysiological events contributing to endothelial dysfunction in CHF as well as several treatment options to reverse those changes.

Keywords: endothelial dysfunction, congestive heart failure, nitric oxide, reactive oxygen species

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [115 - 124]
Pages: 10
DOI: 10.2174/1570161043476447
Price: $65

Article Metrics

PDF: 13